Activity Overview
Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a leading cause of cancer-related morbidity and mortality. Although PSMA PET imaging and PSMA-directed radioligand therapy (RLT) have improved diagnostic and treatment options, clinicians continue to face gaps in knowledge related to patient selection, sequencing, toxicity management, and equitable access to these evolving therapies
This case-based, interactive program is designed to enhance clinician competence and support evidence-based integration of PSMA-directed imaging and RLT into prostate cancer care.
This educational activity is an archive of the live virtual symposium held on April 1, 2026.
Target Audience
This educational program is directed toward medical oncologists, radiation oncologists, nuclear medicine specialists, advanced practice providers, oncology nurses, and other health care practitioners involved in the management of genitourinary cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of PSMA PET/CT in diagnosis, staging, and response assessment across the prostate cancer disease continuum
- Apply evidence-based strategies to integrate and sequence PSMA-directed radioligand therapy (RLT) in prostate cancer care
- Implement best practices to manage treatment-related toxicities associated with PSMA-RLT
- Identify and address barriers to equitable access and delivery of PSMA-targeted therapies in patients with prostate cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here